FrancophonIA/ELRC3.0 huggingface dataset:
English: The table below shows the development of HIV-1 protease mutations and resistance to PIs in virologic failures at endpoint in the GS-US-216-130 trial.
Maltese: It-tabella taħt turi l-iżvilupp ta' mutazzjonijiet ta' protease ta' HIV-1 u reżistenza għal PIs f'fallimenti viroloġiċi fil-punt finali tal-prova GS-US-216-130.
English: HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔* * Using cross-study comparisons to historical pharmacokinetic data
Maltese: HIV Impedituri ta' integrase strand transfer Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔*
English: Cmax, ng/mL AUC24h, ng.h/mL Cmin, ng/mL
Maltese: Cmax, ng/mL AUC24h, ng.siegħa/mL Cmin, ng/mL
English: Treatment difference daily n=131
Maltese: mg darbtejn kuljum n=131
English: Nevirapine 200 mg twice daily nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% darunavir: concentrations were consistent with historical data (↑ nevirapine from CYP3A inhibition)
Maltese: Nevirapine 200 mg darbtejn kuljum nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% darunavir: il-konċentrazzjonijiet kienu konsistenti ma' dejta storika (↑ nevirapine minn impediment ta' CYP3A)
English: - The other ingredients are cellulose, microcrystalline; crospovidone, hydroxypropylcellulose; silica, colloidal anhydrous; silicified microcrystalline cellulose (cellulose, microcrystalline; silica, colloidal anhydrous) and magnesium stearate (E470b) in the tablet core and poly(vinyl alcohol), macrogol, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172) and red iron oxide (E172) in film coating.
Maltese: - Is-sustanzi mhux attivi l-oħra huma microcrystalline cellulose, crospovidone, hydroxypropylcellulose, colloidal anhydrous silica; silicified microcrystalline cellulose (microcrystalline cellulose, colloidal anhydrous silica) u magnesium stearate (E470b) fil-qalba tal-pillola u poly(vinyl alcohol), macrogol, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172) u red iron oxide (E172) fil-kisja tar-rita.
English: Outcomes darunavir/ritonavir
Maltese: Riżultati darunavir/ ritonavir
English: -The other ingredients arecellulose,microcrystalline;crospovidone, hydroxypropylcellulose; silica, colloidal anhydrous; silicified microcrystalline cellulose(cellulose,microcrystalline; silica, colloidal anhydrous)and magnesium stearate (E470b)in the tablet core and poly(vinyl alcohol), macrogol, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172) -only for 400mgfilm-coated tablets and red iron oxide (E172)in film coating.
Maltese: hydroxypropylcellulose, colloidal anhydrous silica; silicified microcrystalline cellulose (microcrystalline cellulose, colloidal anhydrous silica) u magnesium stearate (E470b) fil-qalba tal-pillola u poly(vinyl alcohol), macrogol, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172) - għal 400 mg pilloli miksijin b'rita biss u red iron oxide (E172) fil-kisja tar-rita.
English: ANTIMALARIALS Artemether/Lumefantrine 80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours artemether AUC ↓ 16% artemether Cmin ↔ artemether Cmax ↓ 18% dihydroartemisinin AUC ↓ 18% dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18% lumefantrine AUC ↑ 175% lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13%
Maltese: MEDIĊINI KONTRA L-MALARJA Artemether/Lumefantrine 80/480 mg, 6 dożi wara 0, 8, 24, 36, 48, u 60 siegħa artemether AUC ↓ 16% artemether Cmin ↔ artemether Cmax ↓ 18% dihydroartemisinin AUC ↓ 18% dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18% lumefantrine AUC ↑ 175% lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔
English: It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles.
Maltese: Huwa selettivament jimpedixxi l-qasma ta' poliproteini Gag-Pol li fihom il-kowd ta' l-HIV fiċ-ċelluli infettati bil-virus, u permezz t'hekk ifixkel il-formazzjoni ta' biċċiet infettivi maturi tal-virus.
English: Digoxin 0.4 mg single dose digoxin AUC ↑ 61% digoxin Cmin ND digoxin Cmax ↑ 29% (↑ digoxin from probable inhibition of Pgp)
Maltese: Digoxin Doża waħda ta' 0.4 mg digoxin AUC ↑ 61% digoxin Cmin ND digoxin Cmax ↑ 29% (↑ digoxin x'aktarx minn impediment ta' P-gp)
English: GS-US-216-130 is a single arm, open-label, Phase III trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with cobicistat in 313 HIV-1 infected adult patients (295 treatment-naïve and 18 treatment-experienced).
Maltese: GS-US-216-130 hija prova tal-Fażi III, open-label, b'fergħa waħda biex tistma lfarmakokinetika, is-sigurtà, it-tollerabbiltà u l-effikaċja ta' darunavir ma' cobicistat fi 313-il pazjent adult infettat bl-HIV-1 (295 li qatt ma ħadu kura qabel u 18 li diġà kienu ħadu kura qabel).
English: These are:
Maltese: Sími:
English: Virogic failures were defined as: never suppressed: confirmed HIV-1 RNA < 1 log10 reduction from baseline and ≥ 50 copies/ml at the week-8; rebound: HIV-1 RNA < 50 copies/ml followed by confirmed HIV-1 RNA to ≥ 400 copies/ml or confirmed > 1 log10 HIV-1 RNA increase from the nadir; discontinuations with HIV-1 RNA ≥ 400 copies/ml at last visit IAS-USA lists In GS-US216-130 baseline phenotype was not available
Maltese: Fallimenti viroloġiċi kienu ddefiniti bħala: qatt ma kienu soppressi: tnaqqis ikkonfermat ta'< 1 log ta' RNA ta' HIV-1 mil-linja bażi u ≥ 50 kopja/ml fil-ġimgħa 8; reġgħu ġew lura: < 50 kopja/ml ta' RNA ta' HIV-1 segwiti minn RNA ta' HIV-1 ikkonfermat sa ≥ 400 kopja/ml jew żieda kkonfermata ta' > 1 log10 ta' RNA ta' HIV-1
English: The table below shows the efficacy data of the 48 week analyses from the GS-US-216-130 trial:
Maltese: It-tabella taħt turi d-dejta ta' effikaċja tal-analiżi talġimgħa 48 mill-prova GS-US-216-130:
English: Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and not known (frequency cannot be estimated from the available data).
Maltese: Ilkategoriji ta' frekwenza huma definiti kif ġej: komuni ħafna (≥ 1/10), komuni (≥ 1/100 sa < 1/10), mhux komuni (≥ 1/,000 sa < 1/100), rari (≥ 1/10,000 sa < 1/1,000) u mhux magħruf (il-frekwenza ma tistax tiġi stmata mid-data disponibbli).
English: Ethinylestradiol Norethindrone 35 μg/1 mg once daily drospirenone AUC ↑ 58% drospirenone Cmin ND drospirenone Cmax ↑ 15%
Maltese: Ethinylestradiol Norethindrone 35 g/1 darba kuljum drospirenone AUC ↑ 58% drospirenone Cmin ND drospirenone Cmax ↑ 15% ethinylestradiol AUC  30% ethinylestradiol Cmin ND ethinylestradiol Cmax  14%
English: can be combined with anti-HIV medicines belonging to another class [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion inhibitors)].
Maltese: F'ħafna mill-każi Darunavir Krka d.d. jista' jittieħed flimkien ma' mediċini li jagħmlu parti minn klassi oħra [eż. NRTI's (impedituri tan-nucleoside reverse transcriptase), NNRTI's (impedituri tan-non nucleoside reverse transcriptase), antagonisti ta' CCR5 u FIs (impedituri ta' fużjoni)].
English: Treatment difference darunavir/ritonavir
Maltese: Differenza fil-kura darunavir/ ritonavir
English: What Darunavir Krka d.d.looks like and contents of the pack Darunavir Krka d.d.400mg film-coated tablets (tablets):
Maltese: Kif jidher Darunavir Krka d.d. u l-kontenut tal-pakkett Darunavir Krka d.d. 400 mg pilloli miksjin b'rita (pilloli):
English: 600 mg darunavir/100 mg ritonavir twice daily ritonavir oral solution: 80 mg/ml
Maltese: 600 mg darunavir/100 mg ritonavir darbtejn kuljum b' soluzzjoni orali ta' ritonavir: 80 mg/ml
English: always together with 150 milligram of cobicistat or100 milligram of ritonavir.
Maltese: Krka d.d.) flimkien ma' 150 milligramma ta' cobicistat jew 100 milligramma ritonavir darba kuljum.
English: In women receiving darunavir/ritonavir 800/100 mg once daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 33%, 31% and 30% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 29%, 32% and 50% lower, respectively, as compared with postpartum.
Maltese: F'nisa li kienu qed jirċievu darunavir/ritonavir 800/100 mg darba kuljum waqt ittieni trimestru tat-tqala, il-valuri medji intraindividwali għal Cmax, AUC24 siegħa u Cmin ta' darunavir totali kienu 33%, 31% u 30% inqas, rispettivament meta mqabbla ma' wara t-twelid; waqt it-tielet trimestru tat-tqala, il-valuri ta' Cmax, AUC24 siegħa u Cmin għal darunavir totali kienu 29%, 32% u 50% inqas, rispettivament, meta mqabbla ma' wara t-twelid.
English: may develop a skin rash.
Maltese: Ma ġewx studjati.
English: 800 milligram Darunavir Krka d.d.
Maltese: Darunavir Krka d.d. 800 mg
English: Amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (for heart disease) as the therapeutic effect or side effects of these medicines may be increased.
Maltese: Għid lit-tabib tiegħek jekk inti tieħu: - Amlodipine, diltiazem, disopyramide, carvedilol, felodipine,flecainide, lidocaine, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (għall-mard tal-qalb) minħabba li l-effett terapewtiku jew l-effetti sekondarji ta' dawn il-mediċini jistgħu jiżdiedu.
English: 600/100 mg twice
Maltese: 400/100 mg darbtejn kuljum
English: Amitriptyline Desipramine Imipramine Nortriptyline paroxetine AUC ↓ 39% paroxetine Cmin ↓ 37% paroxetine Cmax ↓ 36% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔ sertraline AUC ↓ 49% sertraline Cmin ↓ 49% sertraline Cmax ↓ 44% darunavir AUC ↔ darunavir Cmin ↓ 6% darunavir Cmax ↔
Maltese: Sertraline 50 mg darba kuljum paroxetine AUC ↓ 39% paroxetine Cmin ↓ 37% paroxetine Cmax ↓ 36% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔ sertraline AUC ↓ 49% sertraline Cmin ↓ 49% sertraline Cmax ↓ 44% darunavir AUC ↔ darunavir Cmin ↓ 6% darunavir Cmax ↔
English: 100 milligram between 30 and 40 kilograms 675 milligram
Maltese: 100 milligramma bejn 30 u 40 kilogramma
English: Digoxin 0.4 mg single dose digoxin AUC ↑ 61% digoxin Cmin ND
Maltese: Digoxin Doża waħda ta' 0.4 mg digoxin AUC ↑ 61% digoxin Cmin ND digoxin Cmax ↑ 29% (↑ digoxin x'aktarx minn impediment
English: TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA < 400 copies/ml)
Maltese: Algoritmu ċċensurat TLOVR mhux-VF ibbażat fuq HIV-1 RNA < 50 kopja/ml, minbarra għal TITAN (HIV-1 RNA < 400 kopja/ml)
English: alfuzosin amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine astemizole, terfenadine colchicine when used in patients with renal and/or hepatic impairment (see section ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) elbasvir/grazoprevir cisapride dapoxetine domperidone naloxegol lurasidone, pimozide, quetiapine, sertindole (see section 4.5) triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
Maltese: alfuzosin - amiodarone, bepridil, dronedarone,ivabradine,quinidine, ranolazine - astemizole, terfenadine - colchicine meta jintuża f'pazjenti b'indeboliment tal-kliewi u/jew tal-fwied (ara sezzjoni 4.5) - derivattivi tal-ergot (eż. dihydroergotamine, ergometrine, ergotamine,
English: 800 mg film-coated tablets (tablets):
Maltese: Darunavir Krka d.d. 800 mg pilloli miksjin b'rita (pilloli):
English: ANTIBIOTIC Clarithromycin 500 mg twice daily clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% darunavir AUC ↓ 13% darunavir Cmin ↑ 1% darunavir Cmax ↓ 17% 14-OH-clarithromycin concentrations were not detectable when combined with darunavir/ritonavir.
Maltese: ANTIBIJOTIKU Clarithromycin 500 mg darbtejn kuljum clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% darunavir AUC ↓ 13% darunavir Cmin ↑ 1% darunavir Cmax ↓ 17% Konċentrazzjonijiet ta' 14-OH-clarithromycin ma kinux b'tali mod li setgħu jiġu identifikati meta ngħata flimkien ma' darunavir/ritonavir.
English: Darunavirgiven with low dose ritonavir may be considered as an alternative.
Maltese: Darunavir/ritonavir jista' jitqies bħala alternattiva.
English: The steady-state pharmacokinetic parameters of darunavir were comparable when boosted with cobicistat versus ritonavir.
Maltese: Il-parametri farmakokinetiċi ta' darunavir fl-istat fiss kienu kumparabbli meta kien intensifikat b'cobicistat versus ritonavir.
English: These results were confirmed in the analysis of data at 96 weeks of treatment in the TITAN trial, with 60.4% of patients in the darunavir/ritonavir arm having HIV-1 RNA < 50 copies/ml at week 96 compared to 55.2% in the lopinavir/ritonavir arm [difference: 5.2%, 95% CI (-2.8; 13.1)].
Maltese: Dawn ir-riżultati kienu kkonfermati fl-analiżi ta' dejta fis-96 ġimgħa ta' kura fil-prova TITAN, b'60.4% tal-pazjenti fil-fergħa ta' darunavir/ritonavir li kellhom HIV-1 RNA < 50 kopja/m fis-96 ġimgħa meta kienu mqabbla ma' 55.2% fil-fergħa ta' lopinavir/ritonavir [differenza: 5.2%, 95% CI (-2.8; 13.1)].
English: ART-experienced paediatric patients from the age of 3 to < 6 years The pharmacokinetics, safety, tolerability and efficacy of darunavir/ritonavir twice daily in combination with other antiretroviral agents in 21 ART-experienced HIV-1 infected paediatric patients aged 3 to < 6 years and weighing 10 kg to < 20 kg was evaluated in an open-label, Phase II trial, ARIEL.
Maltese: Pazjenti pedjatriċi mill-età ta' 3 snin sa , 6 snin b'esperjenza ta' ART Il-farmakokinetika, is-sigurtà, it-tollerabilità u l-effikaċja ta' darunavir/ritonavir darbtejn kuljum flimkien ma' mediċini antiretrovirali oħrajn f'21 pazjent pedjatriku infettati bl-HIV-1 li kienu diġà ħadu kura b'ART fil-passat, li kellhom minn 3 sa < 6 snin u li jiżnu minn 10 kg sa < 20 kg, ġew evalwati fi prova ta' Fażi
English: When used for birth control, alternative methods of nonhormonal contraception are recommended.
Maltese: Meta użati għall-kontroll tat-twelid, metodi alternattivi ta' kontraċezzjoni mhux ormonali huma rrakkomandati.
English: is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV) infection.
Maltese: Darunavir Krka d.d. huwa mediċina antiretrovirali użat għat-trattament ta' infezzjoni bil-Virus Uman talImmunodefiċjenza (HIV).
English: The Darunavir Krka d.d.
Maltese: Kif taħżen Darunavir Krka d.d.
English: Treatment with darunavir/cobicistat 800/150 mg during pregnancy results in low darunavir exposure (see section 5.2), which may be associated with an increased risk of treatment failure and an increased risk of HIV transmission to the child.
Maltese: It-trattament b'darunavir/cobicistat 800/150 mg waqt it-tqala jwassal għal esponiment baxx għal darunavir (ara sezzjonijiet 5.2) li jista' jiġi assoċjat ma' żieda fir-riskju ta' falliment viroloġiku u żieda fir-riskju ta' trasmissjoni talinfezzjoni tal-HIV lit-tarbija.
English: The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown.
Maltese: L-effetti ta' esponiment sistemiku għoli għal fluticasone fuq il-livelli ta' ritonavir filplażma mhumiex magħurfa.
English: Darunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).
Maltese: Darunavir Krka d.d., mogħti flimkien ma' doża baxxa ta' ritonavir huwa indikat, flimkien ma' prodotti mediċinali antiretrovirali oħra, għall-kura ta' pazjenti b'infezzjoni bil-virus uman tal-immunodefiċjenza (HIV-1) (ara sezzjoni 4.2).
English: Darunavir/ritonavir 800/100 mg once daily N=343
Maltese: darunavir/ ritonavir 800/100 mg darba kuljum N=343
English: Darunavir/ritonavir 800/100 mg once daily + OBR N=294
Maltese: Riżultati darunavir/ritonavir 800/100 mg darba kuljum + OBR N=294
English: Furthermore, AUC of the sum of active moieties of rifabutin (parent drug + 25-Odesacetyl metabolite) was increased 1.6fold, while Cmax remained comparable.
Maltese: AUC tat-total tan-nofsijiet attivi ta'rifabutin (mediċina oriġinali + ilmetabolit 25-O-desacetyl) żdiedet b'1.6 drabi aktar, filwaqt li s-Cmax baqgħet kumparabbli.
English: might increase the risk for elevated potassium levels by drospirenone.
Maltese: Darunavir Krka d.d.jista' jżid ir-riskju ta' żieda fil-livelli tal-potassium minn drospirenone.
English: Imputations according to the TLOVR algorithm Based on a normal approximation of the difference in % response NC=F
Maltese: Imputazzjonijiet skont l-algoriżmu TLOVR Ibbażat fuq l-approssimazzjoni normali tad-diferenza fil-% tar-rispons NC=F
English: At week 48, the virologic response, defined as the percentage of patients with confirmed plasma viral load < 50 HIV-1 RNA copies/ml, was evaluated in 16 paediatric patients 15 kg to < 20 kg and 5 paediatric patients 10 kg to < 15 kg receiving darunavir/ritonavir in combination with other antiretroviral agents (see section 4.2 for dosage recommendations per body weight).
Maltese: HIV-1 RNA kopji/ml, ġie evalwat f'16-il pazjent pedjatriku li jiżnu minn 15 kg sa < 20 kg u 5 pazjenti pedjatriċi li jiżnu minn 10 kg sa < 15 kg li kienu qed jirċievu darunavir/ritonavir flimkien ma' mediċini antiretrovirali oħrajn (ara sezzjoni 4.2 għal rakkomandazzjonijiet dwar id dożaġġ skont il-piż tal-ġisem).
English: These active substances include e.g.: alfuzosin amiodarone, bepridil, dronedarone,ivabradine,quinidine, ranolazine astemizole, terfenadine colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) elbasvir/grazoprevir cisapride dapoxetine domperidone naloxegol lurasidone, pimozide, quetiapine, sertindole (see section 4.5) triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil simvastatin lovastatin and lomitapide (see section 4.5) dabigatran, ticagrelor (see section 4.5).
Maltese: derivattivi tal-ergot (eż. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - elbasvir/grazoprevir - cisapride - dapoxetine - domperidone - naloxegol - lurasidone, pimozide, quetiapine, sertindole (ara sezzjoni 4.5) - triazolam, midazolam mogħti mill-ħalq (għal attenzjoni dwar midazolam li jingħata b'mod parenterali, ara sezzjoni 4.5) - sildenafil - meta jintuża għall-kura ta' pressjoni għolja fl-arterji tal-pulmun,
English: 600 milligram Darunavir Krka d.d.
Maltese: Darunavir Krka d.d. 600 mg
English: All subjects darunavir/cobicistat 800/150 mg once daily + OBR N=313
Maltese: L-individwi kollha darunavir/cobicistat 800/150 mg darba kuljum + OBR N=313
English: Medicinal products that may be affected by darunavir boosted with cobicistat
Maltese: Prodotti mediċinali li jistgħu jiġu affettwati minn darunavir intensifikat b'cobicistat
English: The evidence of efficacy of darunavir/ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial ARTEMIS in antiretroviral treatment-naïve HIV-1 infected patients comparing darunavir/ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen).
Maltese: L-evidenza tal-effikaċja ta' darunavir/ritonavir 800/100 mg darba kuljum hija bbażata fuq l-analiżi ta' dejta ta' 192 ġimgħa mill-prova tal-Fażi III, randomised, ikkontrollata, open-label ARTEMIS f'pazjenti infettati b'HIV-1 li qatt ma' ħadu kura b'ART qabel fejn darunavir/ritonavir 800/100 mg darba kuljum tqabbel ma' lopinavir/ritonavir 800/200 mg kuljum (mogħti fi skeda ta' darbtejn kuljum jew darba kuljum).
English: Darunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.
Maltese: Darunavir Krka d.d., mogħti flimkien ma' doża baxxa ta' ritonavir huwa indikat, flimkien ma' prodotti mediċinali antiretrovirali oħra, għall-kura ta' pazjenti b'infezzjoni bil-virus uman tal-immunodefiċjenza (HIV-1).
English: CORTICOSTEROIDS
Maltese: TAL-KALĊJU
English: In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Maltese: F'xi pazjenti b'infezzjoni avvanzata tal-HIV u storja ta' infezzjonjiet opportunistiċi, sinjali u sintomi ta' infjammazzjoni minn infezzjonijiet ta'qabel tista' sseħħ ftit wara li jinbeda trattament kontra l-HIV.
English: Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir and clonazepam.
Maltese: Huwa rrakkomandat monitoraġġ kliniku meta darunavir intensifikat jingħata flimkien ma' clonazepam.
English: HIV-1 RNA < 50 copies/ml median CD4+ cell count change from baseline (x 10
Maltese: HIV-1 RNA < 50 kopja/ml il-medjan ta' tibdil flgħadd ta' ċelluli CD4+ mil-linja bażi (x106/l)c
English: darunavir/ritonavir 600/100 mg twice daily N=298
Maltese: darunavir/ ritonavir 600/100 mg darbtejn kuljum N=298
English: Treatment-experienced darunavir/cobicistat 800/150 mg once daily + OBR N=18
Maltese: Diġà ħadu kura qabel darunavir/cobicistat 800/150 mg darba kuljum + OBR N=18
English: 375 milligram darunavir + 50 milligram ritonavir twice a day between 30 and 40 kilograms
Maltese: Doża waħda hija bejn 15-il kilogramma u 30 kilogramma 375 milligramma darunavir + 50 milligramma ritonavir darbtejn kuljum bejn 30 u 40 kilogramma
English: In the evening, take one 600 milligram Darunavir Krkad.d.tablettogether with 100 milligram ritonavir.
Maltese: - Filgħodu, ħu pillola waħda ta' 600 milligramma Darunavir Krka d.d. flimkien ma' 100 milligramma ritonavir.
English: Each film-coated tablet contains 400mg or 800mg darunavir.
Maltese: Kull pillola miksija b'rita fiha 400 mg jew 800 mg darunavir.
English: Boosted darunavir can be expected to increase the plasma concentrations of calcium channel blockers.
Maltese: Darunavir intensifikat jista' jkun mistenni li jżid il-konċentrazzjonijiet ta' imblokkaturi tal-kanali tal-kalċju fil-plażma.
English: Darunavir must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.
Maltese: Darunavir għandu dejjem jingħata mill-ħalq flimkien ma doża baxxa ta' ritonavir li jservi ta' intensifikatur farmakokinetiku u flimkien ma' prodotti mediċinali antiretrovirali oħra.
English: Darunavir/ritonavir 600/100 mg twice daily + OBR N=296
Maltese: darunavir/ritonavir 600/100 mg darbtejn kuljum + OBR N=296
English: darunavir/ritonavir 600/100 mg twice daily N=296
Maltese: darunavir/ ritonavir 600/100 mg darbtejn kuljum N=296
English: Concomitant use of colchicine and boosted darunavir may increase the exposure to colchicine.
Maltese: colchicine u darunavir intensifikat jista' jżid l-esponiment għal colchicine.
English: Immune reconstitution inflammatory syndrome
Maltese: sindrome infjammatorju ta' rikostituzzjoni immuni
English: EU/1/17/1248/009 30 film-coated tablets EU/1/17/1248/010 90 film-coated tablets
Maltese: EU/1/17/1248/009 90 pillola miksijin b'rita:
English: Darunavir/ritonavir 800/100 mg once daily N=294
Maltese: darunavir/ ritonavir 800/100 mg darba kuljum N=294
English: Darunavir/ritonavir N=80
Maltese: Riżultati fit-48 ġimgħa darunavir/ritonavir N=80